Facebook
Twitter
LinkedIn
ForwardPulse - Going Against the Gr-ADA: Metformin Use in Prediabetes
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Prediabetes is a disease that affects nearly 1 in 3 American adults. Lifestyle interventions focused on exercising and losing weight is the gold standard of treatment to lower patients’ blood sugar and reduce their risk of developing type 2 diabetes. From a pharmacologic standpoint, metformin has the most evidence supporting its use to prevent/delay the progression of prediabetes to type 2 diabetes. Metformin for prediabetes has been considered in guidelines since as early as 2005. However, with new evidence and updated guidelines, the clinical significance of metformin use in prediabetes remains to be in question. This presentation will review evidence assessing the effect of metformin prediabetes and if there is a benefit for its use in prediabetic patients.
Target Audience
Pharmacist
Learning Objectives
Identify the diagnostic criteria and incidence of prediabetes
Discuss current guidance surrounding treatment of prediabetes
Describe evidence assessing the effect of metformin in prediabetes
Additional Information
| Attachment | Size |
|---|---|
 Audience Disclosure slide - Janosik.pptx | 64.6 KB |
 Abstract Handout - Janosik.docx | 45.35 KB |
| pulse 2-8-23.docx | 16.1 KB |
| PULSE - Metformin in Prediabetes.pptx | 2.47 MB |
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Prediabetes is a disease that affects nearly 1 in 3 American adults. Lifestyle interventions focused on exercising and losing weight is the gold standard of treatment to lower patients’ blood sugar and reduce their risk of developing type 2 diabetes. From a pharmacologic standpoint, metformin has the most evidence supporting its use to prevent/delay the progression of prediabetes to type 2 diabetes. Metformin for prediabetes has been considered in guidelines since as early as 2005. However, with new evidence and updated guidelines, the clinical significance of metformin use in prediabetes remains to be in question. This presentation will review evidence assessing the effect of metformin prediabetes and if there is a benefit for its use in prediabetic patients.
Jack Janosik, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.